Evidence map›Paper›PMID 37449176›Full record

ArticleHeliyon2023

Personal recovery among people with opioid use disorder during treatment with extended-release naltrexone.

Anne Marciuch, Bente Birkeland, Jūratė Šaltytė Benth, Kristin Klemmetsby Solli, Lars Tanum, Ida Mathisen, Bente Weimand

Open access · goldAbstract read
In one paragraph

Article in Heliyon, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Anne MarciuchDepartment of Research and Development in Mental Health, Akershus University Hospital, Loerenskog, Norway.
Bente BirkelandDepartment of Psychosocial Health, University of Agder, Kristiansand, Norway.
Jūratė Šaltytė BenthInstitute of Clinical Medicine, Campus Ahus, University of Oslo, Norway.
Kristin Klemmetsby SolliDepartment of Research and Development in Mental Health, Akershus University Hospital, Loerenskog, Norway.
Lars TanumDepartment of Research and Development in Mental Health, Akershus University Hospital, Loerenskog, Norway.
Ida MathisenFaculty for Health Science, Oslo Metropolitan University, Oslo, Norway.
Bente WeimandDepartment of Research and Development in Mental Health, Akershus University Hospital, Loerenskog, Norway.
University of Oslo · NOOsloMet – Oslo Metropolitan University · NOAkershus University Hospital · NOUniversity of Agder · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: Recovery from substance use disorders (SUD) has traditionally been equated with abstinence. "Personal recovery" however emphasizes recovery as a unique and personal process, supported by changes in connectedness, hope, identity, meaning and empowerment. This study aimed to examine personal recovery in people receiving extended-release naltrexone (XR-NTX); specifically investigate changes in personal recovery during treatment, identify groups of participants following distinct trajectories of recovery, and characteristics predicting group-belonging. Methods: Overall change in recovery (Questionnaire about the Process of Recovery, QPR) score was assessed by linear mixed model in a subsample of 135 people with opioid use disorder (OUD) participating in a 24 + 28-week trial of XR-NTX. Growth mixture model was used to identify potential groups of people following distinct trajectories of personal recovery. Results: Overall, there was a significant change in QPR score during treatment. Four groups with distinct recovery trajectories were identified: "initially low- increase" (G1), "initially average- no change" (G2), "initially high- no change" (G3) and "initially high- increase" (G4). The groups were different with regards to level of psychological distress, social support, and the use of benzodiazepines. In addition, previous participation in opioid agonist treatment programs, current pain, life satisfaction, employment, heroin craving and previous use of heroin also differed between groups. Conclusions: Personal recovery among people receiving XR-NTX follows different trajectories, and various factors are associated with personal recovery. Particular attention regarding psychological distress, social support and heroin use among patients commencing XR-NTX treatment is important to facilitate successful recovery trajectories.

Indexed as

Extended-release naltrexoneOpioidsOpioid use disorderPersonal recoveryQPRXR-NTX

Identifiers

PMID37449176
PMCPMC10336734
OpenAlexW4383093164

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.